NCT00110981已完成4 期
A Multicenter, Open-Label, Pilot Trial to Evaluate the Effectiveness and Safety of ENBREL(r) in Combination With Narrowband UVB Phototherapy for the Treatment of Psoriasis
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Amgen
- 入组人数
- 86
- 主要终点
- Proportion of subjects achieving Psoriasis Area Severity Area (PASI) 75 at Week 12
研究概览
简要总结
The purpose of this study is to evaluate the safety and effectiveness of combination therapy with etanercept and narrow-band (NB) UVB phototherapy for the treatment of psoriasis in a pilot study. This is a Phase 4 clinical study being conducted under an Amgen Investigational New Drug Application (IND).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Chronic plaque psoriasis eligible for systemic therapy and NB-UVB in the opinion of the investigator - Psoriasis Activity and Severity Index (PASI) greater than or equal to 15 and at least 25% of individual plaques must be considered severe - Patients must have body surface area (BSA) involvement of greater than or equal to 5% - Before any study-specific procedure, subject must sign and date the appropriate written informed consent - Negative urine pregnancy test within 7 days before the first dose of study drug in all women (except those surgically sterile or at least 5 years postmenopausal) - Sexually active subjects of childbearing potential must agree to use medically acceptable form of contraception during screening and throughout the study
排除标准
- •Prior phototherapy - Current or prior treatment with any tumor necrosis factor (TNF) antagonist, including etanercept, infliximab and adalimumab - Erythrodermic, pustular or guttate psoriasis - Evidence of skin conditions (e.g., eczema) other than psoriasis that would interfere with study-related evaluations of psoriasis - Evidence of active infections such as fevers, chills, sweats, or history of untreated Lyme disease and active severe infections within 4 weeks before screening visit or between the screening and baseline visits - History of immune compromised health [e.g., human immunodeficiency virus (HIV) positive status] - History of any cutaneous malignancy at any time, including squamous or basal cell carcinomas or melanoma - History of non-cutaneous cancer within 5 years - Actinic keratosis or atypical moles - History of alcohol or drug abuse within 12 months of screening visit - Current enrollment in another clinical study and treatment with another experimental drug or approved therapy for experimental use within 30 days prior to etanercept administration - Severe comorbidities as outlined in ENBREL(r) Package Insert: diabetes mellitus requiring insulin, congestive heart failure of any severity, myocardial infarction (within less than or equal to 52 weeks before screening), unstable angina pectoris, oxygen-dependent severe pulmonary disease, tuberculosis or tuberculosis exposure, chronic hepatitis B or hepatitis C, systemic lupus erythematosus, history of multiple sclerosis or other demyelinating disease, transverse myelitis, optic neuritis or epilepsy, uncontrolled hypertension (defined as systolic blood pressure greater than 180 mm Hg or diastolic blood pressure greater than 110 mm Hg) - Contraindications according to the ENBREL(r) Package Insert - Evidence of open cutaneous ulcers - Evidence of photosensitivity disorder (e.g., polymorphous light eruption) - Nursing mothers, female subjects planning on becoming pregnant or male subjects planning a pregnancy with their spouse/partner while in the study - Subjects that cannot commit to all the assessments required by the protocol - Known photosensitivity or known sensitivity to any of the excipients or products to be administered during dosing - Any disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures
研究组 & 干预措施
Single-arm
Experimental
干预措施: NB-UVB (Device)
Single-arm
Experimental
干预措施: Etanerept (Drug)
Single-arm
Experimental
干预措施: Etanercept (Drug)
结局指标
主要结局
Proportion of subjects achieving Psoriasis Area Severity Area (PASI) 75 at Week 12
时间窗: 3 months
次要结局
- Time to PASI 75 responses(Variable)
- Proportion of subjects achieving PASI 90 at Week 12(3 months)
- Improvement in PASI at Week 12(3 months)
- Improvement in body surface area (BSA) involved with psoriasis at Week 12(3 months)
- Improvement in physician global assesssment of psoriasis, including an assessment of the proportion of subjects achieving clear or almost clear status at Week 12(3 months)
- Improvement in patient global assesssment of psoriasis at Week 12(3 months)
- Improvement in Dermatology Life Quality Index (DLQI) at Week 12(3 months)
- Subject incidence of serious adverse events (SAEs) and events of medical interests (EMI) at Week 12(3 months)
研究者
相似试验
尚未招募
3 期
Evaluating the Efficacy and Safety of Cleanser, Serum, and Sunscreen Products for Facial Redness.RednessNCT05961579Goldman, Butterwick, Fitzpatrick and Groff20
招募中
3 期
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 MutationMetastatic Breast CancerNCT05696626LeonaBio600
已完成
2 期
A Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Participants With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naiveHepatitis C, ChronicNCT02993250Janssen Pharmaceutical K.K.33
Unknown
3 期
Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 DiabetesType 2 Diabetes MellitusNCT02089126LG Life Sciences230
终止
1 期
A Study of CN1 in Combination With CN401 in Adult Patients With Relapsed/Refractory Lymphoid MalignanciesRelapsed Lymphoid MalignanciesRefractory Lymphoid MalignanciesNCT04880564Curon Biopharmaceutical (Australia) Co Pty Ltd7